NanoString technology distinguishes anti-TIF-1g+from anti-Mi-2+dermatomyositis patients

Preusse C, Eede P, Heinzerling L, Freitag K, Koll R, Froehlich W, Schneider U, Allenbach Y, Benveniste O, Schaenzer A, Goebel H, Stenzel W, Radke J (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Neuromuscular Disorders Elsevier

Publisher: PERGAMON-ELSEVIER SCIENCE LTD

City/Town: OXFORD

Pages Range: S52-S52

Conference Proceedings Title: NEUROMUSCULAR DISORDERS

DOI: 10.1016/j.nmd.2021.07.034

Involved external institutions

Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Pitié-Salpêtrière University Hospital / Hôpital universitaire Pitié-Salpêtrière FR France (FR) Justus-Liebig-Universität Gießen DE Germany (DE)

How to cite

APA:

Preusse, C., Eede, P., Heinzerling, L., Freitag, K., Koll, R., Froehlich, W.,... Radke, J. (2021). NanoString technology distinguishes anti-TIF-1g+from anti-Mi-2+dermatomyositis patients. Neuromuscular Disorders, S52-S52. https://dx.doi.org/10.1016/j.nmd.2021.07.034

MLA:

Preusse, C., et al. "NanoString technology distinguishes anti-TIF-1g+from anti-Mi-2+dermatomyositis patients." Neuromuscular Disorders (2021): S52-S52.

BibTeX: Download